Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
29 Avril 2024 - 10:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will
host an investor event and conference call on May 13, 2024 at 4:00
PM Western European Summer Time (11:00 AM Eastern Time) to discuss
the primary results from SEQUOIA-HCM (
Safety,
Efficacy, and
Quantitative
Understanding of
Obstruction
Impact of
Aficamten in
HCM), which are being presented in a Late Breaking
Clinical Trial session at Heart Failure 2024, an International
Congress of the European Society of Cardiology. The event will be
held at the Pestana Palace Lisboa Hotel in Lisbon, Portugal in the
Lustiano I room, and simultaneously webcasted online.
Members of Cytokinetics’ management will be
joined by:
- Martin Maron, M.D., Director,
Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical
Center, and Principal Investigator of SEQUOIA-HCM
- Gregory Lewis, M.D., Jeffrey and
Mary Ellen Jay Chair and Section Head, Heart Failure Medical
Director, Cardiopulmonary Exercise Testing Laboratory, Professor of
Medicine, Harvard Medical School
- Caroline Coats, M.D., Ph.D., Lead
Clinician, West of Scotland Inherited Cardiac Conditions Service,
Honorary Senior Lecturer, School of Cardiovascular and Metabolic
Health, University of Glasgow
- Perry Elliott, M.D., Professor of
Cardiovascular Medicine, Director of the Institute for
Cardiovascular Science, University College London
Interested parties must register to attend in
person or online at
https://cytokinetics-SEQUOIA-HCM-investor-event.open-exchange.net/registration.
Registered attendees may access the virtual event platform by
visiting the Investor & Media section of the Cytokinetics
website at www.cytokinetics.com. A link to the webcast replay will
be archived on the Cytokinetics website until November 13,
2024.
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory submissions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in two
ongoing Phase 3 clinical trials: MAPLE-HCM, evaluating aficamten as
monotherapy compared to metoprolol as monotherapy in patients with
obstructive HCM and ACACIA-HCM, evaluating aficamten in patients
with non-obstructive HCM. Cytokinetics is also developing omecamtiv
mecarbil, a cardiac muscle activator, in patients with heart
failure. Additionally, Cytokinetics is developing CK-586, a cardiac
myosin inhibitor with a mechanism of action distinct from aficamten
for the potential treatment of HFpEF, and CK-136, a cardiac
troponin activator for the potential treatment HFrEF and other
types of heart failure, such as right ventricular failure resulting
from impaired cardiac contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the C-shaped logo are
registered trademarks of Cytokinetics in the U.S. and certain other
countries.
Contact:Cytokinetics Diane WeiserSenior Vice
President, Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Cytokinetics (NASDAQ:CYTK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024